Drug intelligence / Profile preview

Cy5.5@SAPD

Development stage
Preclinical
Lead developer
Lanzhou University
Modality
Nanoparticles → Drug Delivery Systems, Peptides
Administration
Intravenous
01

Overview

**Cy5.5@SAPD** is an experimental near-infrared fluorescent self-assembled peptide-DTPA nanoparticle developed as a dual-targeting theranostic candidate for glioblastoma multiforme. It comprises a cyclic Arg-Gly-Asp-Lys-Leu-Ala-Lys peptide containing an RGD integrin-binding motif and a KALK mitochondria-targeting motif, with Cyanine5.5 conjugated to enable near-infrared fluorescence imaging. The nanoparticle showed preferential uptake in U87MG glioblastoma cells, affinity for integrin alpha-V beta-3, mitochondrial damage-associated apoptosis, and preclinical antitumor and imaging potential. Cy5.5@SAPD itself is the non-radiolabeled fluorescent nanoparticle; a separate technetium-99m-labeled derivative, Cy5.5@SAPD-99mTc, was evaluated for combined SPECT and near-infrared fluorescence imaging. ([pubs.rsc.org](https://pubs.rsc.org/en/content/articlepdf/2021/na/d1na00597a))

Other names
Cy5.5-SAPDCy-5.5-SAPDCy 5.5-SAPDCy5.5@SAPD
02

Targets

αVβ3 (Integrin αVβ3)CASP3 (Caspase-3)

Beyond the preview

Go deeper on Cy5.5@SAPD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cy5.5@SAPD.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call